New studies on respiratory syncytial virus (RSV) in both adults and young children show that infections are linked to a ...

A study presented at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute ...

Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

A recent study highlights the alarming increase in death risk associated with respiratory syncytial virus (RSV) among adults.

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...

1 Horn et al, “Disparities in Risk Factors for Severe Respiratory Syncytial Virus Disease among Adults in the United States”, Abstract presented at National Foundation for Infectious Diseases ...

Adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) have a 2.7-fold increased risk of death within a year compared to the general population.

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...